Home › Trials › NCT06726720

Observational study of patients with non-small cell lung cancer starting approved treatments from AstraZeneca

A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs

AstraZeneca · NCT06726720

This study looks at how well AstraZeneca's approved treatments work for people with different stages of non-small cell lung cancer as they start their therapy.

Quick facts

Study typeObservational
Enrollment300 (estimated)
Ages18 Years and up
SexAll
SponsorAstraZeneca (industry)
Locations52 sites (Aix-en-Provence and 51 other locations)
Trial IDNCT06726720 on ClinicalTrials.gov

What this trial studies

This study is an ambispective, observational, multicenter, and multicohort investigation focusing on patients with non-small cell lung cancer (NSCLC) who are initiating approved drugs developed by AstraZeneca or in collaboration with them. It includes three cohorts based on the stage of NSCLC: resectable, unresectable, and metastatic. Patients will be enrolled if they have received or will receive these approved treatments, with data collected retrospectively and prospectively. The study aims to assess the real-world effectiveness of these treatments in various clinical settings.

Who should consider this trial

Good fit: Ideal candidates for this study are adult patients aged 18 and older with histologically or cytologically proven non-small cell lung cancer who are starting approved treatments from AstraZeneca.

Not a fit: Patients currently participating in interventional clinical trials for NSCLC may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of approved NSCLC treatments in real-world settings, potentially improving patient outcomes.

How similar studies have performed: Other observational studies have shown success in assessing real-world treatment outcomes for NSCLC, making this approach both relevant and potentially impactful.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult patients (≥ 18 years old)
* Patients with histologically or cytologically proven NSCLC
* Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks.
* Informed patients who consent to participate in the study as per local regulations.

Exclusion Criteria:

* Patients participating in an interventional clinical trial for NSCLC\*

  \* with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment
* Patients already enrolled in another module of the cohort in UMBREALUNG
* Patients under safeguard of justice, curatorship or guardianship

Where this trial is running

Aix-en-Provence and 51 other locations

+2 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance, observational, real world study, RWE, non-small cell lung cancer, multi-cohort, Ambispective, Prospective, Retrospective, Durvalumab, Osimertinib

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.